$45.51 $0.30 (0.7%)

04:00 PM EST on 12/06/19

GlaxoSmithKline plc (ADR) (NYSE:GSK)

CAPS Rating: 3 out of 5

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Current Price $45.51 Mkt Cap $85.6B
Open $45.40 P/E Ratio 18.73
Prev. Close $45.21 Div. (Yield) $1.99 (4.4%)
Daily Range $45.28 - $45.57 Volume 502,209
52-Wk Range $37.60 - $46.01 Avg. Daily Vol. 2,861,781

Caps

How do you think NYSE:GSK will perform against the market?

Add Stock to CAPS Watchlist

All Players

1,384 Outperform
88 Underperform
 

All-Star Players

284 Outperform
22 Underperform
 

Wall Street

5 Outperform
5 Underperform
 

Top NYSE:GSK Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

brokhernowhysher (74.53)
Submitted November 12, 2015

I am a long term investor who appreciates high dividends. Everything I have seen from GSK indicates a company that while struggling currently, has a good long term outlook. They pay a 5% + dividend and management is bullish on their ability to… More

Funzer (< 20)
Submitted November 16, 2007

GSK is revising Avandia product label to reflect negative events such as myocardial ischemia. Since there is no reduction in cardiovascular risks for diabetics, this reduces the long term outlook for the profitablity of this drug product and GSK.

Recent Community Commentary

Read the most recent pitches from players about GSK.

Recs

0
Member Avatar MaestroFool (84.28) Submitted: 8/7/2018 8:46:54 PM : Underperform Start Price: $39.09 NYSE:GSK Score: -6.09

Facing the threat of generic Advair, but also a lot of debt on the balance sheet, forcing GSK to put a lot of their profits toward interest payments. Yet their dividend is one of the highest among their industry peers. This is great for shareholders hanging on for the dividend but not such great news for the long-term growth of the stock. Therefore, underperform.

Recs

0
Member Avatar DLandress79 (29.14) Submitted: 7/24/2018 2:08:05 PM : Outperform Start Price: $38.70 NYSE:GSK Score: +5.47

A PART OF MY "LONG" MIX

Recs

0
Member Avatar TMFGBudwell (22.21) Submitted: 10/30/2017 6:29:53 AM : Outperform Start Price: $33.10 NYSE:GSK Score: +15.00

Improving fundamentals, new management.

Leaderboard

Find the members with the highest scoring picks in GSK.

Score Leader

niwhsa

niwhsa (79.30) Score: +165.61

The Score Leader is the player with the highest score across all their picks in GSK.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
niwhsa 79.30 11/20/2008 Underperform 3Y $19.14 +137.77% +303.38% +165.61 0 Comment
stockpickeraz 27.31 1/16/2009 Underperform 5Y $20.59 +121.05% +279.65% +158.60 0 Comment
lwc123 < 20 1/8/2009 Underperform 3Y $22.11 +105.84% +255.38% +149.54 0 Comment
stoneyg72 87.09 4/1/2009 Underperform 3W $17.68 +157.36% +295.07% +137.71 0 Comment
longterm007 64.29 10/31/2008 Underperform 5Y $21.77 +109.04% +239.38% +130.35 0 Comment
TRGoodvsEvil 99.31 7/6/2009 Underperform 5Y $20.00 +127.50% +255.71% +128.21 0 Comment
MIKEP75731 39.79 5/22/2009 Underperform 5Y $19.18 +137.25% +257.42% +120.17 1 Comment
janiceelaine < 20 10/6/2008 Underperform 3Y $23.77 +91.46% +201.47% +110.01 0 Comment
PurePwnage 99.39 11/27/2009 Underperform 5Y $24.64 +84.67% +190.45% +105.78 0 Comment
Durp 93.25 9/15/2006 Underperform 3W $28.59 +59.17% +154.68% +95.51 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GSK.